학술논문

Pooled Safety Data from Phase 3 Studies of Epicutaneous Immunotherapy for Peanut Allergy in Children Aged 4-11 Years.
Document Type
Article
Source
Journal of Allergy & Clinical Immunology; 2022 Supplement, Vol. 149 Issue 2, pAB33-AB33, 1p
Subject
Language
ISSN
00916749